San Diego, USA / Shanghai, China, Sept. 6, 2024，ABM Therapeutics, a clinical-stage biopharmaceutical company dedicated to the focus on treating primary brain tumors and brain metastases today announced that the company will present the interim results of an Phase 1 clinical trial using ABM-1310 in treating recurrent primary brain tumors at the annual meeting of the European Society of Medical Oncology (ESMO) in Barcelona, Spain on Sept 15, 2024.

 

 

The annual meeting of ESMO is one of the largest and most prominent global oncology conferences. The clinical research progress of the innovative ABM-1310 developed by ABM Therapeutics will be presented in an oral presentation session by the leading investigator, Professor Li, Wenbin from The Capital Medical University, Beijing Tiantan Hospital. Our team looks forward to in-depth discussions with oncology experts, business partners and investors from around the world.

 

 

About ABM Therapeutics

ABM Therapeutics, a clinical-stage biopharmaceutical company dedicated with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, with a special emphasis on brain cancer and cancer metastases. ABM has been building its broad and robust proprietary pipeline to establish a brain medicine R&D platform through collaboration with Contract Research Organizations (CROs). ABM’s pipeline includes several programs in various stages of discovery and development, many of which have improved brain permeability to address the unmet needs of treating cancers and metastases in the brain.